Alert Data News | Business | Companies | UK | Chemicals, Pharmaceuticals, Biotechnology

Byotrol Plc

Thu, 29 Jul 2010 16:00:03 +0100

Byotrol Plc - Result of AGM
BYOT - leading AIM listed anti-microbial hygiene company, is pleased to announce that all resolutions put to shareholders at today's annual general meeting were duly passed. Enquiries: Byotrol plc ...

AstraZeneca PLC

Thu, 29 Jul 2010 15:00:01 +0100

AstraZeneca PLC - Directorate Change
AZN - NEW NON-EXECUTIVE DIRECTOR AstraZeneca today announced that Dr Bruce Burlington is to join the Board of Directors as a Non-Executive Director, with effect from 1 August 2010. Dr Burlington will also become a member of the Board's Science Committee. Dr Burlington spent 17 years of his ...

AstraZeneca PLC

Thu, 29 Jul 2010 13:21:55 +0100

Strong quarter for AstraZeneca as FDA panel backs Brilinta
AstraZeneca shares are on the rise this morning after the firm posted a strong set of financials for the second quarter and celebrated a recommendation for approval from US advisory panel for its bloo...

AstraZeneca PLC

Thu, 29 Jul 2010 13:21:34 +0100

AstraZeneca strong performer
Turning to larger companies AstraZeneca is a strong performer. The groupâ€™s potential blockbuster heart drug Brilinta has received the backing of a US advisory panel.

BASF Plc

Thu, 29 Jul 2010 11:21:16 +0100

Chemicals maker BASF sees Q2 earnings triple
Second-quarter profits at BASF SE more than tripled as a recovering global economy boosted demand and industry restocked inventories after the recession, the chemicals company said...

AstraZeneca PLC

Thu, 29 Jul 2010 11:21:16 +0100

AstraZeneca ups guidance as profits rise | Digital Look
Pharmaceutical giant AstraZeneca had a double dose of good news today as it jumped up the FTSE100 after raising its forecasts for full-year core earnings to between $6.35 and $6.65 a share, up from Ap...

AstraZeneca PLC

Thu, 29 Jul 2010 08:00:12 +0100

AstraZeneca PLC - Second Quarter and Half Year Results (Part 1 of 3)
AZN - Revenue for the second quarter increased by 1 percent at constant exchange rates (CER) to $8,178 million. -Revenue in markets outside the US increased by 5 percent at CER, largely due to the 16 percent increase in Emerging Markets. -US revenue declined by 4 percent at CER, chiefly as a res...

Antisoma Plc

Thu, 29 Jul 2010 08:00:07 +0100

Antisoma's preliminary results for the year ended 30 June 2010
ASM - font-family: Arial, Verdana, Helvetica; font-size: 13px;} td { padding: 3px; } }Antisoma's preliminary results for the year ended 30 June 2010 London, UK, and Cambridge, MA: 29 July 2010 Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces its preliminary results for the year ended 30...

Vernalis Plc

Thu, 29 Jul 2010 08:00:06 +0100

Vernalis Plc - Interim results for six months ended 30 June 2010
VER - LSE: VER Interim results for the six months ended 30 June 2010 Vernalis plc, a leading development stage pharmaceutical company with a broad pipeline of clinical and early stage programmes, today announces its interim results for the six months ended 30 June 2010. Highlights Financia...

Teva Pharmaceuticals Limited

Wed, 28 Jul 2010 12:12:34 +0100

Teva earnings soar yet again, driven by Copaxone
Teva Pharmaceutical Industries has posted another very strong set of financials for the second quarter, boosted by sales of its multiple sclerosis drug Copaxone and a host of generics launches in the ...